Andrew Schwendenman, the Chief Accounting Officer of Replimune Group, Inc., has sold 2,148 shares of the company's common stock. This transaction was executed on November 16, 2026, to cover tax withholding obligations related to the vesting of his restricted stock units (RSUs). Such transactions are common among executives managing their equity compensation and tax liabilities.
Replimune Group, Inc. operates in the biotechnology sector, specifically under the classification of Biological Products (No Diagnostic Substances). The company is based in Woburn, Massachusetts, and is publicly traded under the ticker symbol REPL.
The SEC filing indicates that Schwendenman’s sale was made in accordance with the irrevocable "sell to cover" provision in the RSU award agreements. The shares were sold at a weighted average price of $21.60, with individual transactions occurring at prices ranging from $21.59 to $21.60.
This sale leaves Schwendenman with a total of 97,277 shares of Replimune following the transaction. Such actions can impact investor perceptions and the overall market dynamics within the biotechnology industry, especially as companies navigate their financial strategies and executive compensation practices.
Details were not available in the SEC filing regarding any future actions or filings related to this transaction.
Andrew Schwendenman is not only the Chief Accounting Officer but also plays a significant role in overseeing the financial reporting and accounting operations at Replimune Group, Inc. His expertise in managing financial strategies is crucial as the company continues to innovate in the biotechnology sector.
The SEC filing specifies that the transaction was executed under the 'sell to cover' provision, which is designed to ensure that executives can meet tax obligations without needing to liquidate other assets. This approach is particularly important in the biotechnology industry, where stock-based compensation is a common practice to align the interests of executives with those of shareholders.
Additionally, the filing confirms that the shares sold were part of the common stock of Replimune Group, Inc., which is classified under the Standard Industrial Classification (SIC) code 2836, indicating its focus on biological products that do not include diagnostic substances. This classification underscores the company's commitment to advancing therapeutic solutions in the life sciences sector.
While the filing provides detailed information about the transaction, it does not include any insights into Schwendenman’s overall compensation package, other holdings in Replimune, or any potential future transactions that may be planned. Such information could provide a more comprehensive understanding of his financial interests in the company.
Read Next
Xynos Konstantinos sells shares to cover tax obligations
Martin David Norman sells 4,800 shares of Guardian Pharmacy
Chen Zhiwu Acquires Additional Shares in GigaCloud Technology
Kenneth E. Lebensburger Jr. Acquires Additional Shares in GigaCloud
Radakovich Lynn Vojvodich Reports Stock Transactions for Figma
Ferring Russell Shea acquires 2,588 RSUs at Firefly Aerospace









